Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

Ph.D., Orexigen President and CEO. "Based on our preclinical data, we believe that OREX-003 has the potential to have an improved metabolic profile and be a more effective long-term option in the management of schizophrenia and a number of related conditions."

About OZ-101

The OZ-101 clinical trial is a double-blind, placebo-controlled clinical trial evaluating the combination of olanzapine plus zonisamide SR versus olanzapine plus placebo in 75 patients with schizophrenia over 16 weeks at nine centers in the U.S. Preclinical studies conducted by Orexigen have demonstrated that zonisamide mitigated both weight gain and elevated blood glucose associated with olanzapine through novel mechanisms. The clinical trial is currently enrolling. More information can be found at http://www.clinicaltrials.gov.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... (NYSE Amex: CUR ) announced that the ongoing ... in amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was ... http://www.neuralstem.com/neuralstem-in-the-news (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The trial ... injections. About Neuralstem ...
... N.J., Nov. 13, 2011 Pharmasset, Inc. (Nasdaq: ... Capital Markets 8th Annual Healthcare Conference to be held November ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ... 3:00 PM (ET). To access a simultaneous webcast ...
... Discharge 1-2-3 of Schaumburg, IL has been ... Innovation Awards for their Discharge 1-2-3 Composer™. The ... Theater on Tuesday, November 8, with more than 1400 people ... the Chicago region,s foremost recognition of the most innovative new ...
Cached Biology Technology:Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 3
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... Leuven, Belgium - When a blood vessel clogs up, a ... die. However, working with mice, VIB scientists connected to the ... with severe hypoxia from dying. The muscles seem to adapt ... force that animals also use when hibernating, but that has ...
... critical difference between flu viruses that infect birds and humans, ... avian flu strains and aid in the development of vaccines ... a virus,s ability to infect humans depends on whether it ... surface of human respiratory cells. Now that we know ...
... in marine biomedical laboratories at Scripps Institution of Oceanography ... information about the fundamental biological processes inside a marine ... to treat cancer in humans. The finding could lead ... human diseases. A research team led by Bradley ...
Cached Biology News:Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 2MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3Researchers uncover key trigger for potent cancer-fighting marine product 2
... Extraction Software reads and processes ... prepare microarray data for analysis. ... one 1-year license for ... accounts ,one CD-ROM containing Feature ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... handling system from Molecular Devices provides precise ... instrument. The system handles a variety of ... 384- and 1536-welland is the first to ... been optimized to dispense from four different ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: